ClinicalTrials.gg
CompletedNCT01013571Updated Mar 21, 2012

Self Titration With Apidra to Reach Target Study (START)

A Phase 4 interventional study of insulin glargine and Apidra (insulin glulisine) in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 1 site in Canada. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2012-03-21.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
48th of 175
493 · median 253
Started
2009
with 9 others
Phase 4
103 of 176
2 open now
Registered
71st of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2009, is one of 103 in phase 4, and was the 71st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at breakfast in Canadian patients with inadequately controlled T2DM after optimization of basal insulin, compared with an HCP-managed titration algorithm. The primary endpoint for assessment of this objective is the percent of patients reaching a target HbA1c \<=7.0% without severe hypoglycemia at the end of the study.

Secondary Objective:

Secondary objectives of the study are to compare the effect of the two different insulin glulisine titration algorithms (patient-managed versus HCP-managed) on the following:

  • change in HbA1c, FG, and 7-point glucose profile at Week 24 and Week 36
  • satisfaction with treatment (DTSQc for patient and questionnaire for HCP) at Week 36
  • change in weight at Week 24 and Week 36
  • incidence of hypoglycemia
  • insulin doses
  • resource utilization (rural/urban, blood glucose meter test strips, lancets, HCP visits, telephone calls, and hospitalizations)
  • adherence with the patient-managed monitoring algorithm
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Run-in phase:

  • T2DM
  • Treated for at least 3 months with a basal insulin (insulin glargine, NPH, detemir) +/- oral antidiabetic drugs (OADs) with an >7.0% or insulin naive (2-3 OADs) with an HbA1c >=7.8% (historic HbA1c result up to 3 months of screening is acceptable)

Randomized treatment phase:

  • Completed run-in phase
  • HbA1c >7.0% and >= 1 episode of confirmed nocturnal hypoglycemia (BG \<4.0 mmol/L) or >= 2 measurements of FG \<=6.0 mmol/L within the previous week Patients who completed the run-in phase with HbA1c >7.0% and did not meet the randomization criteria will continue titrating insulin glargine and be followed until the end of study.

Exclusion criteria

Exclusion Criteria:

  • No food intake before lunch (noon)
  • Unstable diet intake or significant changes to current diet regimen
  • Nightshift worker
  • Type 1 Diabetes Mellitus
  • Subjects unwilling to inject insulin or perform self-monitoring blood glucose
  • Pregnant, alcohol or drug abuse
  • Active cancer or any other disease or condition which in the opinion of the investigator would make the subject unsuitable for participation in the study
  • Any clinical significant laboratory findings that in the judgment of the investigator would preclude safe completion of the study
  • Known allergies to study drugs

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    1

    12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed

    Drug: insulin glargine · Drug: Apidra (insulin glulisine)

  • Experimental
    2

    12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed

    Drug: insulin glargine · Drug: Apidra (insulin glulisine)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of subjects reaching target HbA1c <=7.0% without severe hypoglycemia

    Time frame: at week 36 (end of study)

Secondary outcomes

  1. Change in HbA1c, FG, and 7-point glucose profile

    Time frame: from Week 12 (randomization) to Week 24 and Week 36

  2. Change in weight

    Time frame: from Week 12 to Week 24 and to Week 36

  3. Incidence of hypoglycemia

    Time frame: Week 12 , Week 24 and Week 36

  4. Treatment satisfaction (DTSQ for patient )

    Time frame: from Week 12 to Week 36

  5. Adherence with the patient-managed monitoring algorithm

    Time frame: Week 12 , Week 24 and Week 36

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Laval, Canada
08

References and documents

Publications

  • Harris SB, Yale JF, Berard L, Stewart J, Abbaszadeh B, Webster-Bogaert S, Gerstein HC. Does a patient-managed insulin intensification strategy with insulin glargine and insulin glulisine provide similar glycemic control as a physician-managed strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study: a randomized noninferiority trial. Diabetes Care. 2014;37(3):604-10. doi: 10.2337/dc13-1636. Epub 2013 Oct 29. PubMed 24170757 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2009
First posted
Nov 13, 2009
Start
Oct 2009
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Mar 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01013571
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 13, 2009
Start date
Oct 2009
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Mar 21, 2012

Study contacts

Clinical Sciences & Operations
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Insulin glulisine

Start the discussion